Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Dosing Comparison# Retatrutide Dosing# Based on Phase 2 clinical trial protocols (investigational only): Starting dose : 0.5 mg weekly subcutaneous injection Escalation : Gradual increase over 12-24 weeks to target dose (up to 12 mg) Target doses tested : 1, 4, 8, and 12 mg weekly Escalation rationale : Extended 24-week escalation for higher doses reduces GI side effects compared to faster 12-week escalation No commercial formulation exists
Next-Gen Oral Obesity Drugs Novo Nordisk has partnered with U.S.-based Septerna in a deal worth up to $2.2 billion to co-develop oral small molecule therapies targeting obesity and related cardiometabolic diseases
Ive not seen it
This is especially the case for those who were unaware of these severe risks and couldnt factor them into their decision to pursue these drugs
McCall McPhereson: Well, it improves your fertility
As someone whos seen the transformative potential of GLP-1 drugs firsthand, Id like to share an in-depth look at how they work, who they benefit, and the realities of using them
